Identification and validation of coagulation and fibrinolytic-related diagnostic biomarkers for ulcerative colitis by bioinformatics analysis.
| Autor: | Li FY; The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou Province, China., Wu X; Department of Proctology, The First People's Hospital of Bijie, Bijie City, Guizhou Province, China., Yao MF; The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou Province, China., Zhang J; Renhuai Hospital of Traditional Chinese Medicine, Renhuai City, Guizhou Province, China., Mo YJ; Renhuai Hospital of Traditional Chinese Medicine, Renhuai City, Guizhou Province, China. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Medicine [Medicine (Baltimore)] 2024 Sep 06; Vol. 103 (36), pp. e39552. |
| DOI: | 10.1097/MD.0000000000039552 |
| Abstrakt: | Abnormalities in coagulation and fibrinolytic status have been demonstrated to be relevant to inflammatory bowel disease. Nevertheless, there is no study to methodically examine the role of the coagulation and fibrinolysis-related genes in the diagnosis of ulcerative colitis (UC). UC-related datasets (GSE169568 and GSE94648) were originated from the Gene Expression Omnibus database. The biomarkers related to coagulation and fibrinolysis were identified through combining differentially expressed analysis and machine learning algorithms. Moreover, Gene Set Enrichment Analysis and immune analysis were carried out. A total of 4 biomarkers (MAP2K1, CREBBP, TAF1, and HP) were identified, and biomarkers were markedly enriched in pathways related to immunity, such as T-cell receptor signaling pathway, primary immunodeficiency, chemokine signaling pathway, etc. In total, the infiltrating abundance of 4 immune cells between UC and control was markedly different, namely eosinophils, macrophage M0, resting mast cells, and regulatory T cells. And all biomarkers were significantly relevant to eosinophils. Our findings detected 4 coagulation and fibrinolysis-related biomarkers (MAP2K1, CREBBP, TAF1, and HP) for UC, which contributed to the advancement of UC for further clinical investigation. Competing Interests: The authors have no funding and conflicts of interest to disclose. (Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|